Sunvozertinib, marketed as Zegfrovy, offers new hope for certain lung cancer patients. Doctors now use this oral drug to fight advanced non-small cell lung cancer (NSCLC).
The FDA granted accelerated approval on July 2, 2025. This targeted therapy helps adults with locally advanced or metastatic NSCLC. Specifically, it treats cases with EGFR exon 20 insertion mutations. Patients must first progress after platinum-based chemotherapy. An FDA-approved test confirms the mutation.
Sunvozertinib acts as a kinase inhibitor. It binds to and blocks EGFR with exon 20 insertions. Consequently, the drug slows tumor growth effectively. Unlike some older treatments, it shows strong selectivity for mutated EGFR.
Clinical trials supported the approval. The phase 2 WU-KONG1B study enrolled pretreated patients. In this trial, sunvozertinib achieved a 46% overall response rate. Moreover, responses lasted about 11.1 months on average. Patients take 200 mg once daily with food.
However, side effects require monitoring. Common issues include interstitial lung disease, pneumonitis, and gastrointestinal problems. Dermatologic reactions and ocular toxicity can also occur. Embryo-fetal toxicity warns pregnant patients to avoid it.
Overall, Zegfrovy fills a critical gap. Previously, few targeted oral options existed for this mutation. Now, eligible patients gain a convenient pill that may extend survival and improve quality of life. Ongoing trials continue to confirm long-term benefits. Always consult an oncologist for personalized guidance.